Sanofi American Depositary Shares (Each representing one-half of one ordinary share) (SNY) Valuation
Historical valuation analysis based on 1281 data points (2021-09-10 to 2026-10-16)
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accou...
Sanofi American Depositary Shares (Each representing one-half of one ordinary share) trades near its historical valuation range, with most metrics close to their median levels.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|
Sanofi American Depositary Shares (Each representing one-half of one ordinary share) (SNY) Valuation & P/E History
Sanofi American Depositary Shares (Each representing one-half of one ordinary share) (SNY) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry currently trading at $40.56 with a market capitalization of $97.2 billion. This page provides historical valuation analysis for SNY based on 1281 data points covering 2021-09-10 to 2026-10-16...
SNY Valuation Metrics & Historical Range
The valuation table above shows Sanofi American Depositary Shares (Each representing one-half of one ordinary share)'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether SNY is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests SNY is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Sanofi American Depositary Shares (Each representing one-half of one ordinary share).
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is SNY Overvalued or Undervalued?
Sanofi American Depositary Shares (Each representing one-half of one ordinary share) trades near its historical valuation range, with most metrics close to their median levels. The overall valuation percentile of 50 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive SNY is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full SNY analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.SNY trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.